News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–51
Matches
51
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

51 matching headlines

Ticker or company: PFIZ34Main company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. European Commission grants marketing authorization for Pfizer and BioNTech's XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer PFE is set to report its second-quarter 2026 earnings on Aug. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $14.45 billion and 68 cents per share, respectively. Estimates for Pfizer's 2026 earnings …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer (PFE) closed the most recent trading day at $25.25, moving +2.35% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.21%. Meanwhile, the Dow experienced a rise of 1.03%, and the technology-dominated Nasdaq saw a decrease of 0.22%. …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026

As the industry prepares to gather in Boston this August, leaders from Gilead Sciences, GSK, and Pfizer will headline a plenary session exploring how AI and digital technologies are reshaping biopharmaceutical quality. BOSTON, July 28, 2026 /PRNewswire/ -- As the biopharmaceutical industry prepares to …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million in Q2 2026, including $6.2 million from 4Kscore test. Pharmaceutical Revenue: $89 …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer PFE announced that the FDA has accepted the supplemental new drug application (sNDA) for Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), for an expanded use in prostate cancer. The sNDA is seeking approval …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations NEW YORK, July …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies

BluesightCoveer Image ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer's SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows Bluesight, the leader in hospital intelligence solutions, today announced a partnership with …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

Pfizer PFE will announce its second-quarter 2026 earnings on Aug. 4, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

Pfizer (PFE) ended the recent trading session at $24.75, demonstrating a -1.2% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.59%, and the technology-dominated Nasdaq …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned -0.6% over the past …

PFIZ34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.5% PFIZ34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context